logo
We're pocketing a 170% gain on one stock and changing our rating on another

We're pocketing a 170% gain on one stock and changing our rating on another

CNBC27-05-2025

We are selling 50 shares of Broadcom at roughly $233. Following the trade, Jim Cramer's Charitable Trust will own 600 shares of AVGO, decreasing its weighting to 4.15% from about 4.5%. Stocks are surging Tuesday after President Donald Trump announced over the holiday weekend that he agreed to delay a 50% tariff on the European Union. Stronger-than-expected consumer confidence data also lifted stocks, especially those in the consumer discretionary sector. With equities rising across the board, we're taking the other side of the trade and using this strength to lighten up on our Broadcom position. Shares of this semiconductor maker and software company have come all the way back from their post-Liberation Day (April 2) lows and are now trading in positive territory for the year. The stock has also climbed 50% since the company announced a $10 billion share repurchase program on April 7, which was a clear sign of confidence in the company's future and that the sell-off was overdone. Although we continue to like Broadcom for the long term for its fast-growing AI business and VMware, we are downgrading our rating to a 2, meaning we would buy more shares on a pullback. From this sale, we will realize a gain of about 170% on stock purchased in August 2023. We're also increasing our GE Vernova price target to $500 from $460 to account for the recent momentum in its business. The stock has already blown past our initial $460 price target thanks to confirmation of our initial thesis that GE Vernova's gas turbine and grid technology business would become a beneficiary of trade deals. Also, Trump signed an executive order last Friday to boost the U.S. nuclear energy industry. But we are downgrading our GE Vernova rating to a 2. This downgrade does not reflect a shift in our long-term thesis on this energy equipment company, as outlined during our May Monthly Meeting on Wednesday . Instead, don't want to chase this move after the stock's double-digit gain to an all-time high since we initiated the position two weeks ago. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Jim Cramer on Arrowhead Pharmaceuticals (ARWR): 'It Doesn't Make Any Money'
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): 'It Doesn't Make Any Money'

Yahoo

time16 minutes ago

  • Yahoo

Jim Cramer on Arrowhead Pharmaceuticals (ARWR): 'It Doesn't Make Any Money'

We recently published a list of . In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands against other stocks that Jim Cramer discusses. When a caller inquired about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), Cramer said: 'You know, look, it doesn't make any money. I've been waiting for it to do something, break out. I just don't know if it has the horses.' A scientist in a lab coat analyzing a Petri dish surrounded by scientific equipment in a research lab. Arrowhead Pharmaceuticals (NASDAQ:ARWR) develops RNA-based treatments for a wide range of hard-to-treat diseases, with multiple drug candidates in clinical trials targeting conditions such as cardiovascular disorders, liver disease, pulmonary illness, and rare genetic disorders. Additionally, in 2019, Cramer said the following about the company: 'I looked at Arrowhead recently and I didn't see that much. You know, everyone's so excited about it. I don't get that. I have been saying that it's absolutely O.K. to own stocks that have to do with slicing and dicing and genes, but I'm not gonna endorse it for anything other than speculation.' For context, since the above comment was aired, Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock declined more than 75%. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Circle IPO: Stock price today as stablecoin company makes long-awaited NYSE debut
Circle IPO: Stock price today as stablecoin company makes long-awaited NYSE debut

Yahoo

time16 minutes ago

  • Yahoo

Circle IPO: Stock price today as stablecoin company makes long-awaited NYSE debut

The time has come for another highly anticipated arrival on the New York Stock Exchange (NYSE). Circle Internet Group, a stablecoin provider, is making its initial public offering today for $31 a share. Here's everything you need to know about Circle's IPO. Why you're catching the 'ick' so easily, according to science Why AI Is Making 1:1 Meetings Irrelevant Where are the wildfires in Canada? Maps pinpoint the location of fires and air-quality threats from smoke New York-based Circle, led by CEO Jeremy Allaire, is the issuer of USDC, a stablecoin tied to the U.S. dollar and the second-largest stablecoin globally. Circle also offers EURC, a stablecoin tied to the Euro. Circle set its share prices on Wednesday and plans to list its stock today, Thursday, June 5. The offer is expected to close the following day, Friday, June 6. Circle will trade its stock under the ticker CRCL. Circle will trade its shares on the NYSE. Circle's share price for the IPO is $31. The marketed estimate was $27 to $28. There will be 34 million shares of CRCL available. Circle is offering 14.8 million shares, while stockholders are selling 19.2 million shares. In addition, Circle is offering underwriters, like JPMorgan and Goldman Sachs, 30 days to purchase 5.1 million additional shares. The company is set to raise $1.1 billion in its IPO. Circle's current valuation is about $6.9 billion, but once all shares are diluted, it could increase to $8.1 billion. The stock market has experienced volatility under President Trump—especially in response to his 'Liberation Day' tariffs. However, PitchBook reports that some big names, such as Klarna, Discord, and Figma, are still expected to make IPOs this year. Klarna is the likeliest, with a 97% probability. Meanwhile, digital banking services startup Chime Financial is expected to list on the Nasdaq as soon as next week. This post originally appeared at to get the Fast Company newsletter: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Broadcom Q2 Earnings Beat Estimates, Revenues Up Y/Y, Shares Fall
Broadcom Q2 Earnings Beat Estimates, Revenues Up Y/Y, Shares Fall

Yahoo

time16 minutes ago

  • Yahoo

Broadcom Q2 Earnings Beat Estimates, Revenues Up Y/Y, Shares Fall

Broadcom AVGO reported second-quarter fiscal 2025 non-GAAP earnings of $1.58 per share, surpassing the Zacks Consensus Estimate by 0.64% and increasing 43.6% year over revenues increased 20% year over year to $15 billion, surpassing the Zacks Consensus Estimate by 0.37%. Broadcom's revenue growth in the second quarter of fiscal 2025 was driven by strong performance in AI semiconductors and VMware revenues benefited from continued investments from hyperscale partners in AI XPUs and connectivity solutions for AI data shares lost 4.01% in after-hours trading to $249.50 following the fiscal second-quarter results. Broadcom Inc. price-consensus-eps-surprise-chart | Broadcom Inc. Quote Semiconductor solutions revenues (56% of net revenues) totaled $8.4 billion, rising 17% year over year and missing the Zacks Consensus Estimate by 0.17%. AI-related revenues grew 46% year over year to $4.4 billion, which was a major driver of overall revenue growth. This growth was driven by higher shipments of networking solutions to hyperscalers for AI semiconductor revenues declined 5% year over year to $4 the second quarter of fiscal 2025, broadband, enterprise networking and server storage revenues were up revenue was down in the second quarter of fiscal 2025, while wireless revenue also decreased due to software revenues (44% of net revenues) rose 25% year over year to $6.6 billion, bolstered by the successful conversion of enterprise customers to the full VMware Cloud Foundation(VCF) software stack subscription. The non-GAAP gross margin was 79%, expanding 320 basis points (bps) year over and development, as a percentage of net revenues, decreased 210 bps year over year to 10.2%. Selling, general and administrative expenses also decreased 280 bps to 4%.Adjusted EBITDA increased 35% year over year to $10 billion. The adjusted EBITDA margin expanded 720 bps on a year-over-year basis to 66.7%.The non-GAAP operating margin grew 800 bps year over year to 65.3%. As of May 4, 2025, cash and cash equivalents were $9.47 billion compared with $9.31 billion as of Feb. 2, debt (including the current portion of $5.53 billion) was $67.28 billion as of May 4, 2025, compared with $66.58 billion as of Feb. 2, generated $6.55 billion in cash flow from operations compared with $6.11 billion in the previous quarter. The free cash flow was $6.41 billion compared with $6.01 billion in the prior of March 31, 2025, the company paid out a cash dividend of $0.59 per share of common stock, totaling $2.78 billion. For third-quarter fiscal 2025, Broadcom expects revenues of $15.8 billion, suggesting an increase of 21% from the prior-year period's semiconductor revenues are projected to grow 60% year over year to $5.1 billion, whereas non-AI semiconductor revenues are expected to reach $4 Software revenues are expected to grow 16% year over year to $6.7 revenues are anticipated to grow 25% year over year to $9.1 the third quarter of fiscal 2025, enterprise networking and broadband are expected to continue to grow storage, wireless and industrial are expected to be largely EBITDA is expected to be 66% of projected company anticipates the non-GAAP diluted share count to be 4.97 billion. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Currently, Broadcom carries a Zacks Rank #2 (Buy). Amphenol APH, Juniper Networks JNPR and Upwork UPWK are some other top-ranked stocks that investors can consider in the broader Zacks Computer & Technology sector. APH, JNPR and UPWK sport a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks shares have gained 33.2% in the year-to-date period. The Zacks Consensus Estimate for APH's full-year 2025 earnings is pegged at $2.66 per share, up by 1.5% over the past 30 days, suggesting growth of 40.74% from the year-ago quarter's reported shares have lost 4.4% in the year-to-date period. The Zacks Consensus Estimate for JNPR's full-year fiscal 2025 earnings has been revised upward to $2.08 in the past 30 days, suggesting year-over-year growth of 20.93%.UPWK shares have lost 7.7% in the year-to-date period. The Zacks Consensus Estimate for UPWK's full-year 2025 earnings is pegged at $1.14 per share, implying a rise of 9.62% from the year-ago quarter's levels. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amphenol Corporation (APH) : Free Stock Analysis Report Juniper Networks, Inc. (JNPR) : Free Stock Analysis Report Broadcom Inc. (AVGO) : Free Stock Analysis Report Upwork Inc. (UPWK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store